Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S095029 and pembrolizumab in advanced MSI-H/dMMR gastric/GEJ cancer
NCT06116136Phase 2Active, not recruiting
- Sponsor
- Servier
- Start
- Aug 2024
- Primary completion
- Aug 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 15
01
Overview
A Phase 2 trial of sym021 in gastric cancer (GC), gastroesophageal junction cancer, sponsored by Servier. Started Aug 2024; status: active, not recruiting.
02
Drugs
sym021
03
Conditions
gastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT06116136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06116136.